Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Jimin Hwang, Young Joo Han, Dong Keon Yon, Seung Won Lee, Beom Kyung Kim, Se Bee Lee, Min Ho Lee, Seung Hyun Park, Ai Koyanagi, Louis Jacob, Kalthoum Tizaoui, Seung Up Kim, Jae Il Shin, Lee Smith

Article2021

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

Evangelos Terpos, Marianna Politou, Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Efrosyni Merkouri, Despina Fotiou, Maria Gavriatopoulou, Panagiotis Malandrakis, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos

Article2022

Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis

Binu V. John, Akash Doshi, Yangyang Deng, Natalie Mansour, A.Sidne Barritt, Andrew M. Moon, George N. Ioannou, Paul Martin, Hann‐Hsiang Chao, Tamar H. Taddei, David Kaplan, Bassam Dahman

Article2022

Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia

Styliani Geronikolou, Işıl Takan, Athanasia Pavlopoulou, Marina Mantzourani, George Chrousos

Article2023

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia: A comprehensive review, release 2 (immunologic perspective)

Kalthoum Tizaoui, Inès Zidi, Masoud Rahmati, Ai Koyanagi, Andreas Kronbichler, Michael Eisenhut, Jae Il Shin, Lee Smith